Lucid Diagnostics Inc.

NasdaqCM:LUCD 주식 리포트

시가총액: US$201.9m

Lucid Diagnostics 경영진

경영진 기준 점검 3/4

Lucid Diagnostics CEO는 Lishan Aklog, Oct2021 에 임명되었습니다 의 임기는 4.58 년입니다. 총 연간 보상은 $712.00K, 42.1% 급여 및 57.9% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $3.89M 가치에 해당하는 회사 주식의 1.93% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 4.4 년과 5.5 년입니다.

핵심 정보

Lishan Aklog

최고경영자

US$712.0k

총 보수

CEO 급여 비율42.13%
CEO 재임 기간4.6yrs
CEO 지분 보유율1.9%
경영진 평균 재임 기간4.4yrs
이사회 평균 재임 기간5.5yrs

최근 경영진 업데이트

Recent updates

LUCD: Higher Future P/E Assumptions Will Support Upside Despite Execution Risks

Analysts have lifted their price target on Lucid Diagnostics by $0.75, citing updated assumptions around the discount rate, revenue growth, profit margins, and a higher future P/E multiple as the key drivers of the change. Analyst Commentary While the higher price target reflects updated modeling assumptions, bearish analysts still flag several areas of concern that readers should keep in mind when thinking about Lucid Diagnostics.

LUCD: Revised Outlook Suggests VA Contract Will Support Future Repricing

Analysts have adjusted their price target on Lucid Diagnostics from $8.25 to $9.00, reflecting updated assumptions on revenue growth, profitability, discount rate, and future P/E expectations. Analyst Commentary Recent research highlights a constructive tone around Lucid Diagnostics, with bullish analysts pointing to updated assumptions on revenue growth, profitability, discount rate, and future P/E expectations as key reasons behind the higher price target of US$9.00.

Poised for success

Lucid Diagnostics' EsoGuard is a novel screening tool for esophageal cancer. It is relatively non-invasive and may become widely accepted soon.

LUCD: VA Contract Will Drive Broader Future Adoption And Repricing

Analysts have raised their price target for Lucid Diagnostics to $8.25. This reflects updated views on fair value, discount rate, revenue growth, profit margin, and a very high anticipated future P/E multiple.

LUCD: VA Contract Will Expand Screening Access And Support Future Upside

Analysts have modestly adjusted their price target for Lucid Diagnostics to reflect slightly updated assumptions on discount rate, revenue growth, profit margin, and future P/E, while keeping their overall fair value estimate steady at $2.50. What's in the News Lucid Diagnostics received a contract from the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test, aimed at expanding access to esophageal precancer testing across the VA healthcare system, which serves more than 9,000,000 enrolled veterans annually (Key Developments).

LUCD: VA Screening Access And Safety Data Will Support Future Upside

Analysts kept their Lucid Diagnostics price target steady at $2.50, pointing to largely unchanged fair value and P/E assumptions, with only small tweaks to the discount rate, revenue growth, and profit margin inputs behind their models. What's in the News Lucid Diagnostics secured a U.S. Department of Veterans Affairs contract for its EsoGuard Esophageal DNA Test, making the test available across the VA's national integrated healthcare system that serves more than 9 million enrolled veterans each year (Key Developments).

LUCD: VA Screening Contract And Real World Data Will Support Future Upside

Analysts have modestly revised their price target on Lucid Diagnostics, citing adjusted assumptions for the discount rate, revenue growth, profit margin, and future P/E that maintain a fair value estimate of $2.50. What's in the News Lucid Diagnostics secured a U.S. Department of Veterans Affairs contract for its EsoGuard Esophageal DNA Test, giving VA hospitals and facilities nationwide a single procurement framework and expanding access across the system that serves more than nine million enrolled veterans annually (Key Developments).

LUCD: VA Contract And Real World Screening Data Will Support Future Upside

Analysts have adjusted their price target for Lucid Diagnostics slightly, maintaining fair value at about US$2.50 while fine tuning assumptions on the discount rate, revenue growth, profit margins and future P/E to reflect updated views on the company’s risk profile and earnings power. What's in the News Lucid Diagnostics secured a contract with the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test, expanding access to esophageal precancer testing across the VA system, which serves more than 9,000,000 enrolled veterans annually (Key Developments).

Lucid Diagnostics: Green Flags, But Dilution And Friction Keep Me Neutral

Jan 26

LUCD: Real World Screening Data Will Support Stronger Long-Term Profit Potential

Analysts have slightly reduced their price target on Lucid Diagnostics, citing updated assumptions that keep fair value steady at $2.50 while reflecting small adjustments to the discount rate, revenue growth, profit margin and future P/E expectations. What's in the News New real world data on Lucid Diagnostics EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device cover 11,991 at risk patients over 18 months of routine clinical use between January 2023 and June 2024 (medRxiv preprint).

LUCD: New Screening Data Will Support Stronger Long-Term Profit Potential

Analysts have raised their price target on Lucid Diagnostics by approximately 25 percent to reflect higher projected revenue growth, slightly improved long term profitability, and a modestly higher valuation multiple despite a small uptick in the assumed discount rate. What's in the News Reported new 18-month real-world data in 11,991 at-risk patients using EsoGuard and EsoCheck for nonendoscopic Barrett's esophagus screening, supporting their utility as scalable, noninvasive tools in routine clinical practice (company announcement) Study authors highlighted excellent safety and tolerability, with EsoCheck achieving a 95% technical success rate, most procedures completed in under two minutes, and no serious adverse events (company announcement) Most patients in the analysis met U.S. gastroenterology society guideline criteria for Barrett's esophagus screening, indicating appropriate physician adoption of EsoGuard and EsoCheck (company announcement) Valuation Changes Fair Value: risen moderately from 2.0x to 2.5x, reflecting a higher implied valuation multiple on forward fundamentals.

Is Lucid Diagnostics (NASDAQ:LUCD) Using Too Much Debt?

Dec 13
Is Lucid Diagnostics (NASDAQ:LUCD) Using Too Much Debt?
User avatar

Expanded Reimbursement And Cash-Pay Programs Will Open Future Markets

Expanding reimbursement coverage and leveraging NCCN guidelines are strategies expected to enhance revenue and credibility with payers.

We're A Little Worried About Lucid Diagnostics' (NASDAQ:LUCD) Cash Burn Rate

May 09
We're A Little Worried About Lucid Diagnostics' (NASDAQ:LUCD) Cash Burn Rate

Lucid Diagnostics (NASDAQ:LUCD) Will Have To Spend Its Cash Wisely

Dec 15
Lucid Diagnostics (NASDAQ:LUCD) Will Have To Spend Its Cash Wisely

Lucid Diagnostics launches stage II lucid test center in California, Texas, Florida, and Ohio

Aug 11

We're Keeping An Eye On Lucid Diagnostics' (NASDAQ:LUCD) Cash Burn Rate

Jul 07
We're Keeping An Eye On Lucid Diagnostics' (NASDAQ:LUCD) Cash Burn Rate

CEO 보수 분석

Lishan Aklog의 보수는 Lucid Diagnostics의 수익에 비해 어떻게 변했나요?
날짜총 보수급여회사 수익
Dec 31 2025n/an/a

-US$71m

Sep 30 2025n/an/a

-US$66m

Jun 30 2025n/an/a

-US$68m

Mar 31 2025n/an/a

-US$71m

Dec 31 2024US$712kUS$300k

-US$53m

Sep 30 2024n/an/a

-US$52m

Jun 30 2024n/an/a

-US$54m

Mar 31 2024n/an/a

-US$55m

Dec 31 2023US$300kUS$300k

-US$53m

Sep 30 2023n/an/a

-US$57m

Jun 30 2023n/an/a

-US$57m

Mar 31 2023n/an/a

-US$60m

Dec 31 2022US$456kn/a

-US$56m

Sep 30 2022n/an/a

-US$53m

Jun 30 2022n/an/a

-US$45m

Mar 31 2022n/an/a

-US$37m

Dec 31 2021US$7mn/a

-US$28m

보상 대 시장: Lishan의 총 보수(USD712.00K)는 US 시장에서 비슷한 규모 기업의 평균(USD1.61M)보다 낮습니다.

보상과 수익: Lishan의 보상은 회사가 적자임에도 증가했습니다.

CEO

Lishan Aklog (59 yo)

4.6yrs
재임 기간
US$712,000
보수

Dr. Lishan Aklog, M.D., serves as an Executive Chairman at Veris Health Inc. since April 2023. He served as Independent Director at ContraFect Corporation since June 14, 2020 until December 04, 2023. Dr. A...

리더십 팀

이름직위재임 기간보수지분
Lishan Aklog
Chairman & CEO4.6yrsUS$712.00k1.93%
$ 3.9m
Shaun O'Neill
President & COO4.2yrsUS$712.00k0.77%
$ 1.5m
Dennis McGrath
Chief Financial Officer8yrsUS$637.00k0.96%
$ 1.9m
Michael Gordon
General Counsel & Secretary4yrsUS$662.00k0.53%
$ 1.1m
Sanford Markowitz
Co-Founder & Strategic Advisorno dataUS$924.54k데이터 없음
Joseph Willis
Co-founder & Strategic Advisorno data데이터 없음데이터 없음
Amitabh Chak
Co-Founder & Strategic Advisorno data데이터 없음데이터 없음
Helen Moinova
Co-Founder & Strategic Advisorno data데이터 없음데이터 없음
Brian deGuzman
Chief Technology & Compliance Officerno data데이터 없음데이터 없음
Suman Verma
Senior VP & Chief Scientific Officer4.6yrs데이터 없음데이터 없음
Matthew Riley
Director of Investor Relationsno data데이터 없음데이터 없음
Deepika Lakhani
Senior VP2.3yrs데이터 없음데이터 없음
4.4yrs
평균 재임 기간
59yo
평균 나이

경험이 풍부한 관리: LUCD의 경영진은 경험이 있음으로 간주됩니다(평균 재임 4.4 년).

이사회 구성원

이름직위재임 기간보수지분
Lishan Aklog
Chairman & CEO8yrsUS$712.00k1.93%
$ 3.9m
Stanley Lapidus
Independent Vice Chairman of the Board & Lead Independent Director4.8yrsUS$188.31k0.18%
$ 361.0k
Ronald Sparks
Independent Director4.6yrsUS$235.81k0.17%
$ 342.9k
Jacque Sokolov
Independent Director5.1yrsUS$225.81k0.17%
$ 342.9k
Dennis Matheis
Independent Director2yrsUS$205.26k0.42%
$ 843.6k
James Cox
Independent Director8yrsUS$199.62k0.21%
$ 433.5k
Debra White
Independent Director3.8yrsUS$205.81k0.12%
$ 252.3k
Nicholas Shaheen
Chair of Medical Advisory Board8yrs데이터 없음데이터 없음
Michael Smith
Member of Medical Advisory Board8yrs데이터 없음데이터 없음
Srinadh Komanduri
Member of Medical Advisory Board5.8yrs데이터 없음데이터 없음
Stuart Spechler
Member of Medical Advisory Boardno data데이터 없음데이터 없음
Rhonda Souza
Member of Medical Advisory Boardno data데이터 없음데이터 없음
5.5yrs
평균 재임 기간
70yo
평균 나이

경험이 풍부한 이사회: LUCD의 이사회는 경험이 있음으로 간주됩니다(평균 재임 5.5 년).

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/01 22:59
종가2026/05/01 00:00
수익2025/12/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Lucid Diagnostics Inc.는 5명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Edward WooAscendiant Capital Markets LLC
Mark MassaroBTIG
Kyle MiksonCanaccord Genuity